Slide 1: First Quarter 2025 Operating & Financial Results Conference Call / Webinar
First Quarter 2025 Operating & Financial Results Conference Call / Webinar May 15th, 2025 9AM Eastern Time NASDAQ :LTRN
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements r
Slide 3: Contents and Speakers
Contents Speakers Panna Sharma David Margrave 01 Introduction CEO and President CFO 02 2025 Q1 Highlights 03 Financial Highlights 04 Q&A 2
Slide 4: 1st Quarter Highlights 1 of 2
ü Completion of LP-184 Phase 1a clinical trial with 62-65 patients enrolled across a range of solid tumors expected by 2025 end of June 2025. 1st Quarter ü Additional patient data readout from the HARMONIC™ Trial evaluating LP-300 in never-smokers with non-small cell Highlights lung cancer anticipat
Slide 5: 1st Quarter Highlights 2 of 2
2025 ü Planning commercial availability and launch of select RADR® AI modules for the scientific and research 1st Quarter community to foster collaborative, open-source innovation in cancer drug development. Highlights ü Obtained further independent preclinical confirmation of LP-184 hypersensitivit
Slide 6: CEO quote on pivotal inflection point
"This quarter represents a pivotal inflection point in our clinical and technological development. As we approach full enrollment in our LP-184 Phase 1a trial and prepare for an additional data readout for our LP-300 Harmonic Trial, including initial data from our Asian expansion cohort, we are posi
Slide 7: Financial Updates Q1 2025
Financial Updates Q1 2025 Summary Results of Operations Balance Sheet Highlights & Summary Three Months Ended March 31, (unaudited) 03/31/2025 12/31/2024 2025 2024 (unaudited) Operating expenses: Cash, Cash Equivalents & 19,721,651 24,013,063 Marketable Securities General and administrative $ 1,510,
Slide 8: Lantern's diverse & unique AI-driven pipeline of drug programs
Lantern’s diverse & unique AI-driven pipeline of 11 drug programs including RADR® collaborations and Starlight Therapeutics Lantern Pharma (NASDAQ: LTRN) Lead Orphan Rare Fast Indication Discovery Preclinical Phase I Phase II Drug Pediatric Track Candidate Non-Small Cell Lung Cancer LP-300 for Never
Slide 9: Starlight's pipeline is focused on multiple CNS indications in adult and pediatric patients
Starlight’s pipeline is focused on multiple CNS indications in both adult and pediatric patients Starlight Therapeutics ADULT CNS CANCERS Orphan Lead Candidate Indication Discovery Preclinical Phase I Phase II Designation RPDD Fast Track First Recurrent Glioblastoma* STAR-001 Newly Diagnosed MGMT Un
Slide 10: Recent publications highlighting the clinical value of RADR
Recent publications highlighting the clinical value of RADR® in the development of Lantern’s drug candidates POSTER | AACR ANNUAL MEETING 2025 Identification of biomarkers for drug candidate LP-184 in precision oncology applications https://bit.ly/3SgY1rv POSTER | AACR IMMUNO-ONCOLOGY CONFERENCE 202
Slide 11: 2025 Objectives
2025 Objectives A Breakthrough Year for Lantern ● Complete Phase 1a clinical trial for LP-184; pursue Phase 1b/2 and investigator led trial(s) ● Advance enrollment in first-in-human clinical trial for LP-284 in NHL + other cancers T ● Report initial clinical data for Asian cohort in the Harmonic™ Tr
Slide 12: Connect With Us
NASDAQ: LTRN CONNECT WITH US CONNECT WITH US IR Contact: IR Contact: IR@lanternpharma.com IR@starlighttthera.com 1-972-277-1136 www.lanternpharma.com www.starlightthera.com @LanternPharma @Starlight_Thera linkedin.com/company/lanternpharma linkedin.com/company/starlightthera